Precigen, Inc. (PGEN) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good evening, and welcome to the President's Full Year 2024 Financial Results and Business Update Call. At this time, all lines are in listen-only mode. Following the prepared remarks, there will be a question and answer session. Please note that this event is being recorded. I would now like to turn the conference over to Steve Harrison, from Investor Relations. Please go ahead. Thank you, Alan, and thank you for everyone joining us this afternoon. With me today are Dr. Helen Sabzavary, President and CEO of Precision, Harry Tomasian, our CFO, Phil Tennant, our Chief Commercial Officer, and Ritul Shah, our Chief Operating Officer. Before we begin, let me briefly review our forward-looking statements. During today's call, we will make various forward-looking statements. Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ from those indicated by our forward-looking statements. Please read the safe-hour statement contained in our most recent SEC filings, as well as risk factors contained in precedent filings. With that, I would like to now turn the call over to Dr. Sabzabari. Helen? Thank you, Steve, and thank you to all for taking the time to join us for our year-end 2024 update. It is indeed a transformative time at the Precision, and as we are on the verge of commercializing our lead asset, PRGM 2012 in RRP, potentially bringing a treatment to this patient population with high unmet needs. From discovery in 2020, phase one initiation in 2021, phase two with breakthrough designation and accelerated approval pathway in 2023, followed by publication in science translation and presentation of the groundbreaking data at ASCO in 2024. T...